These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. Reginster JY; Seeman E; De Vernejoul MC; Adami S; Compston J; Phenekos C; Devogelaer JP; Curiel MD; Sawicki A; Goemaere S; Sorensen OH; Felsenberg D; Meunier PJ J Clin Endocrinol Metab; 2005 May; 90(5):2816-22. PubMed ID: 15728210 [TBL] [Abstract][Full Text] [Related]
4. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454 [TBL] [Abstract][Full Text] [Related]
5. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678 [TBL] [Abstract][Full Text] [Related]
6. Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis. Compston J Osteoporos Int; 2005 Jan; 16 Suppl 1():S4-6. PubMed ID: 15480571 [TBL] [Abstract][Full Text] [Related]
7. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. Adami S Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247 [TBL] [Abstract][Full Text] [Related]
8. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575 [TBL] [Abstract][Full Text] [Related]
9. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Borgström F; Jönsson B; Ström O; Kanis JA Osteoporos Int; 2006 Dec; 17(12):1781-93. PubMed ID: 17009083 [TBL] [Abstract][Full Text] [Related]
10. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Meunier PJ; Reginster JY Osteoporos Int; 2003; 14 Suppl 3():S66-76. PubMed ID: 12730769 [TBL] [Abstract][Full Text] [Related]
11. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Reginster JY; Deroisy R; Jupsin I Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204 [TBL] [Abstract][Full Text] [Related]
12. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review. Boonen S Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842 [TBL] [Abstract][Full Text] [Related]
13. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373 [TBL] [Abstract][Full Text] [Related]
14. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages. Ortolani S; Vai S Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319 [TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Kanis JA; Johansson H; Oden A; McCloskey EV Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148 [TBL] [Abstract][Full Text] [Related]